The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ETER901: A randomized, open-label, phase III trial of anlotinib in combination with anti-PD-L1 antibody benmelstobart (TQB2450) versus nab-paclitaxel in first-line treatment of recurrent or metastatic triple-negative breast cancer.
 
Jiayu Wang
No Relationships to Disclose
 
Binghe Xu
No Relationships to Disclose
 
Quchang Ouyang
No Relationships to Disclose
 
Zhihong Wang
No Relationships to Disclose
 
Qingyuan Zhang
No Relationships to Disclose
 
Yu Ren
No Relationships to Disclose
 
Jincai Zhong
No Relationships to Disclose
 
Tao Sun
No Relationships to Disclose
 
Zhongsheng Tong
No Relationships to Disclose
 
Wenxian Zhou
No Relationships to Disclose
 
Xiaojia Wang
No Relationships to Disclose
 
Yahua Zhong
No Relationships to Disclose
 
Xiaohua Zeng
No Relationships to Disclose
 
Yuee Teng
No Relationships to Disclose
 
Jing Sun
No Relationships to Disclose
 
Yunhong Xia
No Relationships to Disclose
 
Cuizhi Geng
No Relationships to Disclose
 
Fuming Qiu
No Relationships to Disclose
 
Huadong Zhao
No Relationships to Disclose
 
Ning Liao
No Relationships to Disclose